Literature DB >> 12504054

How low is the alpha/beta ratio for prostate cancer?

Jian Z Wang1, M Guerrero, X Allen Li.   

Abstract

PURPOSE: It has been suggested recently that the alpha/beta ratio for human prostate cancer is low (around 1.5 Gy), and much debate on the evidence for such a low value is ongoing. Analyses reported so far ignored the contribution of tumor repopulation. Extremely low alpha values and unrealistic cell numbers of tumor clonogens are found in these studies. In this paper, we present a comprehensive analysis of the updated clinical data to derive a self-consistent set of parameters for the linear-quadratic (LQ) model. METHODS AND MATERIALS: The generalized LQ model, considering the effects of dose rate, sublethal damage repair, and clonogenic proliferation, was used to analyze the recently reported clinical data for prostate cancer using either external-beam radiotherapy or brachytherapy. Three LQ parameters, alpha, alpha/beta, and the repair time, were determined based on the clinical finding that the external-beam radiotherapy and the 125I and (103)Pd permanent implants are biologically equivalent. The tumor control probability model was used also to analyze the clinical data to obtain an independent relationship of alpha/beta vs. alpha and to estimate clonogenic cell numbers for patients in different risk groups.
RESULTS: Based on the analysis of clinical data and a consideration of repopulation effect, we have derived a self-consistent set of LQ parameters for prostate cancer: alpha = 0.15 +/- 0.04 Gy(-1), alpha/beta = 3.1 +/- 0.5 Gy. Our analysis indicates the half-time of sublethal damage repair to be in the range from 0 to 90 min with a best estimate of 16 min. The best estimate of clonogenic cell numbers in prostate tumors is found to range from 10(6) to 10(7) according to the patient risk level. These values are more realistic than those derived previously (only 10-100).
CONCLUSION: The effect of tumor repopulation is not negligible in determining the LQ parameters for prostate cancer, especially for the low-dose-rate permanent implants. Analysis of clinical data for prostate cancer with corrections for damage repair and repopulation effects results in a low alpha/beta ratio of 3.1 Gy. Unrealistic clonogenic cell numbers and extremely small values of alpha reported in the literature can be resolved by correcting for repopulation effect. The LQ parameters derived presently from the clinical data are consistent with reports of intrinsic radiosensitivity in vitro.

Entities:  

Mesh:

Year:  2003        PMID: 12504054     DOI: 10.1016/s0360-3016(02)03828-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  60 in total

Review 1.  Technological advances in radiation therapy for prostate cancer.

Authors:  Mehee Choi; Arthur Y Hung
Journal:  Curr Urol Rep       Date:  2010-05       Impact factor: 3.092

2.  Impact of prolonged fraction dose-delivery time modeling intensity-modulated radiation therapy on hepatocellular carcinoma cell killing.

Authors:  Xiao-Kang Zheng; Long-Hua Chen; Xiao Yan; Hong-Mei Wang
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

3.  A comparison of HDR brachytherapy and IMRT techniques for dose escalation in prostate cancer: a radiobiological modeling study.

Authors:  M Fatyga; J F Williamson; N Dogan; D Todor; J V Siebers; R George; I Barani; M Hagan
Journal:  Med Phys       Date:  2009-09       Impact factor: 4.071

4.  Alpha/beta (α/β) ratio for prostate cancer derived from external beam radiotherapy and brachytherapy boost.

Authors:  Philip S Boonstra; Jeremy M G Taylor; Beata Smolska-Ciszewska; Katarzyna Behrendt; Tomasz Dworzecki; Marzena Gawkowska-Suwinska; Brygida Bialas; Rafal Suwinski
Journal:  Br J Radiol       Date:  2016-02-23       Impact factor: 3.039

5.  Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial.

Authors:  Dario Pasalic; Deborah A Kuban; Pamela K Allen; Chad Tang; Shane M Mesko; Stephen R Grant; Alexander A Augustyn; Steven J Frank; Seungtaek Choi; Karen E Hoffman; Quynh-Nhu Nguyen; Sean E McGuire; Alan Pollack; Mitchell S Anscher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-03-02       Impact factor: 7.038

6.  Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for a phase I-II clinical study.

Authors:  Francesca Botta; Marta Cremonesi; Mahila E Ferrari; Ernesto Amato; Francesco Guerriero; Andrea Vavassori; Anna Sarnelli; Stefano Severi; Guido Pedroli; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-03       Impact factor: 9.236

7.  A note on modeling of tumor regression for estimation of radiobiological parameters.

Authors:  Hualiang Zhong; Indrin Chetty
Journal:  Med Phys       Date:  2014-08       Impact factor: 4.071

8.  On the need to compensate for edema-induced dose reductions in preplanned (131)Cs prostate brachytherapy.

Authors:  Z Jay Chen; Jun Deng; Kenneth Roberts; Ravinder Nath
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-05       Impact factor: 7.038

9.  Choline PET based dose-painting in prostate cancer--modelling of dose effects.

Authors:  Maximilian Niyazi; Peter Bartenstein; Claus Belka; Ute Ganswindt
Journal:  Radiat Oncol       Date:  2010-03-18       Impact factor: 3.481

10.  The "PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II)--a survey among Italian radiation oncologists on radical radiotherapy in prostate cancer.

Authors:  Berardino De Bari; Filippo Alongi; Pierfrancesco Franco; Patrizia Ciammella; Tarik Chekrine; Lorenzo Livi; Barbara A Jereczek-Fossa; Andrea Riccardo Filippi
Journal:  Radiol Med       Date:  2013-05-27       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.